The prognostic value of PD-L1 in the treatment of advanced hepatocellular carcinoma with combination of apatinib and karelizumab

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100044694

Enrollment

Unknown

Registered

2021-03-25

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced hepatocellular carcinoma

Interventions

control group:They were treated with apatinib and karelizumab combined system, without TACE and other local treatment

experimental group:The patients with HCC were treated with apatinib and karelizumab combined with TACE

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All the patients were diagnosed according to the criteria of diagnosis and treatment of primary liver cancer (2019 Edition) and Barcelona standard. In addition, the patients should meet the following criteria: (1) advanced HCC confirmed by imaging histology; (2) not suitable for surgery; (3) child Pugh a or B (<= 7); (4) at least one measurable lesion; and (5) ECoG score of 0-1.

Exclusion criteria

Exclusion criteria: (1) Patients with severe hepatic and renal insufficiency; (2) patients with pregnancy, reproductive and embryogenic tumors, active liver disease and metastatic liver cancer; (3) patients with hepatitis A, hepatitis B, hepatitis C and other types of hepatitis; (4) patients with hematological diseases, autoimmune diseases and other diseases.

Design outcomes

Primary

Measure	Time frame
OS;PFS;	—

Secondary

Measure	Time frame
ORR;TTP;	—

Countries

China

Contacts

Public ContactJinhua Hu

Shandong Provincial Hospital

386860155@qq.com+86 15553163901

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026